COMMON WARTS (VERRUCA VULGARIS)
Clinical trials for COMMON WARTS (VERRUCA VULGARIS) explained in plain language.
Never miss a new study
Get alerted when new COMMON WARTS (VERRUCA VULGARIS) trials appear
Sign up with your email to follow new studies for COMMON WARTS (VERRUCA VULGARIS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New gel could zap away common warts in just weeks
Disease control Recruiting nowThis study tests a medicated gel called YCANTH on common warts caused by HPV. About 300 people aged 2 and older with at least one wart will apply the gel or a fake version. The goal is to see if the gel safely clears all warts by day 84.
Matched conditions: COMMON WARTS (VERRUCA VULGARIS)
Phase: PHASE3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated May 26, 2026 05:54 UTC
-
New gel shows promise for stubborn warts in extended trial
Disease control Recruiting nowThis study follows people who previously took part in a wart treatment study (COVE-2 or COVE-3) to see if YCANTH gel is safe and works over a longer period. Participants with remaining warts can get up to 4 more treatments, applied every 21 days. The goal is to clear all warts, a…
Matched conditions: COMMON WARTS (VERRUCA VULGARIS)
Phase: PHASE3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
Wart war: vitamin D3 vs. acyclovir injections face off
Symptom relief Recruiting nowThis study compares two injected treatments for skin warts: vitamin D3 and the antiviral drug acyclovir. Forty people aged 12 and older with common, plantar, flat, or nail warts will receive injections every two weeks for up to four sessions. The goal is to see which treatment cl…
Matched conditions: COMMON WARTS (VERRUCA VULGARIS)
Phase: PHASE4 • Sponsor: Riphah International University • Aim: Symptom relief
Last updated May 22, 2026 13:51 UTC